This new generation of biochemical and genetic screens
are highly automated, high-throughput assays (upward of
50 000 assay points per day in a number of cases). The
resultant screening capacity at many companies is signifi-
cantly larger than the potential input from in-house chemical
libraries. Since screening capacity is no longer the ratelimiting
step, many major pharmaceutical companies became
very interested in screening natural products (either as crude
extracts or as prefractionated “peak libraries”) as a low-cost
means of discovering novel lead compounds. A good
illustration, though not an anti-cancer compound, was the
discovery at Merck Research Laboratories of a new antibiotic,
platensimycin, through the testing of a library of 250 000
natural product extracts in a custom-designed assay involving
an engineered strain of Staphylococcus aureus incorporating
the fatty acid synthase pathway enzyme, FabF
This new generation of biochemical and genetic screens
are highly automated, high-throughput assays (upward of
50 000 assay points per day in a number of cases). The
resultant screening capacity at many companies is signifi-
cantly larger than the potential input from in-house chemical
libraries. Since screening capacity is no longer the ratelimiting
step, many major pharmaceutical companies became
very interested in screening natural products (either as crude
extracts or as prefractionated “peak libraries”) as a low-cost
means of discovering novel lead compounds. A good
illustration, though not an anti-cancer compound, was the
discovery at Merck Research Laboratories of a new antibiotic,
platensimycin, through the testing of a library of 250 000
natural product extracts in a custom-designed assay involving
an engineered strain of Staphylococcus aureus incorporating
the fatty acid synthase pathway enzyme, FabF
การแปล กรุณารอสักครู่..